Skip to main content Skip to section navigation Skip to footer
Stock Information
chevron_left Back to CastleBiosciences.com
Castle Biosciences, Inc. IR Home
  • Overview
  • News & Events keyboard_arrow_down
    • Press Releases
    • IR Events
    • Presentations
    • In The Media
    • Annual Meeting
    • Email Alerts
  • Company Info keyboard_arrow_down
    • Company Profile
    • Executive Team
    • Annual Reports & Proxy
    • Contacts
    • FAQ
  • Financial Info keyboard_arrow_down
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data keyboard_arrow_down
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • SEC Filings keyboard_arrow_down
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance keyboard_arrow_down
    • Governance Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Corporate Responsibility
  • Resources keyboard_arrow_down
    • Scientific Evidence
  • Stock Information
  • chevron_leftBack to CastleBiosciences.com

In The Media

News & Events

  • Press Releases
  • IR Events
  • Presentations
  • In The Media
  • Annual Meeting
  • Email Alerts
Nov 25, 2023
Physician's Weekly: Standardizing Management and Improving Health Outcomes in BE with an Automated Tissue Systems Pathology Test
Nov 21, 2023
Healio: Gene Expression Profiling May Reduce Unnecessary Biopsies in Melanoma
Nov 20, 2023
The Healthcare Technology Report: The Top 25 Women Leaders in Biotechnology of 2023
Nov 6, 2023
MedTech Genie: Castle Biosciences Delivers Strong Volume Growth in 3Q23 and Makes Major Progress on Profitability
Nov 6, 2023
Physician's Weekly: Tissue Systems Pathology Test Excels in Risk Stratification for LGD Patients over Pathology Review
Nov 3, 2023
GenomeWeb: Castle Biosciences Sees Big Gains in New Testing Niches as Legacy Assays Grow Steadily
Nov 1, 2023
Practical Dermatology: Study: Gene Expression Test IDs Best Patients for Adjuvant Radiation Therapy
Oct 21, 2023
Dermatology Times: 40-GEP Identifies Patients Who Benefit Most From Adjuvant Radiation Therapy With Improved Metastasis-Free Survival of cSCC
Oct 12, 2023
Nasdaq: Behind the Bell: Castle Biosciences
Oct 5, 2023
Practical Dermatology: DecisionDx-Melanoma Outperforms MSKCC Nomogram in Predicting Sentinel Lymph Node Positivity in Melanoma
rss_feed RSS
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • Page 22
  • …
  • Page 26
  • Next Pagearrow_forward
  • emailEmail Alerts
  • location_cityCompany Profile
  • contact_pageContacts
  • rss_feedRSS News Feed
©2026 Castle Biosciences, Inc. All Rights Reserved.
  • Privacy Policy
  • Disclaimer
  • Sitemap
  • Accessibility Statement

Market Data copyright © 2026 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.